SCHEMBL533522

SCHEMBL533522

FC(F)c1nc(-c2cc[c]cc2)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
RAB9A P51151 5/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX5 P09917 1/20 0.37
MAPT P10636 6/20 0.33
NPC1 O15118 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
KMT2A Q03164 4/20 0.33
KDM4E B2RXH2 3/20 0.33
AR P10275 3/20 0.33
MEN1 O00255 3/20 0.33
LMNA P02545 2/20 0.33
ADAM17 P78536 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
LTA4H P09960 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533579 0.82 ALDH1A1 (0.37) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL534352 0.82 PIK3CD (0.38) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL534216 0.76 ALDH1A1 (0.44) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL533303 0.75 ALDH1A1 (0.34) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL533699 0.73 RAB9A (0.44) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL1029102 0.73 ALDH1A1 (0.66) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL534232 0.72 CYP19A1 (0.41) ALDH1A1RAB9ACYP3A4ALOX5MAPT
SCHEMBL533381 0.72 GAA (0.61) ALDH1A1RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL533498 0.71 IDH1 (0.41) ALDH1A1RAB9ACYP3A4ALOX5KMT2A
SCHEMBL533127 0.68 ALOX5 (0.39) ALDH1A1RAB9ACYP3A4ALOX5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP disclosed
CN-102448940-B For the medical composition of glaucomatous treatment or prevention UBE INDUSTRIES, LTD. (JP) 2015-10-21 CN disclosed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 US disclosed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
CN-102448940-A Pharmaceutical composition for treating or preventing glaucoma UBE INDUSTRIES 2012-05-09 CN disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US disclosed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 ALDH1A1 204/4885RAB9A 2549/4885CYP3A4 1198/4885
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 ALDH1A1 256/4885RAB9A 2112/4885CYP3A4 1337/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 ALDH1A1 377/4885RAB9A 1700/4885CYP3A4 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.